Unravelling the Role of PARP1 in Homeostasis and Tumorigenesis: Implications for Anti-Cancer Therapies and Overcoming Resistance

Overview

Journal Cells

Publisher MDPI

Specialties Biochemistry
Biophysics
Cell Biology
Molecular Biology

Date 2023 Jul 29

PMID 37508568

Authors

Taylor Lovsund

Fatemeh Mashayekhi

Amira Fitieh

James Stafford

Ismail Hassan Ismail

Affiliations

Soon will be listed here.

Abstract

Detailing the connection between homeostatic functions of enzymatic families and eventual progression into tumorigenesis is crucial to our understanding of anti-cancer therapies. One key enzyme group involved in this process is the Poly (ADP-ribose) polymerase (PARP) family, responsible for an expansive number of cellular functions, featuring members well established as regulators of DNA repair, genomic stability and beyond. Several PARP inhibitors (PARPi) have been approved for clinical use in a range of cancers, with many more still in trials. Unfortunately, the occurrence of resistance to PARPi therapy is growing in prevalence and requires the introduction of novel counter-resistance mechanisms to maintain efficacy. In this review, we summarize the updated understanding of the vast homeostatic functions the PARP family mediates and pin the importance of PARPi therapies as anti-cancer agents while discussing resistance mechanisms and current up-and-coming counter-strategies for countering such resistance.

References

Cortesi L, Rugo H, Jackisch C . An Overview of PARP Inhibitors for the Treatment of Breast Cancer. Target Oncol. 2021; 16(3):255-282. PMC: 8105250. DOI: 10.1007/s11523-021-00796-4. View

Bryant H, Petermann E, Schultz N, Jemth A, Loseva O, Issaeva N . PARP is activated at stalled forks to mediate Mre11-dependent replication restart and recombination. EMBO J. 2009; 28(17):2601-15. PMC: 2738702. DOI: 10.1038/emboj.2009.206. View

Robson M, Tung N, Conte P, Im S, Senkus E, Xu B . OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Ann Oncol. 2019; 30(4):558-566. PMC: 6503629. DOI: 10.1093/annonc/mdz012. View

Hoxhaj G, Manning B . The PI3K-AKT network at the interface of oncogenic signalling and cancer metabolism. Nat Rev Cancer. 2019; 20(2):74-88. PMC: 7314312. DOI: 10.1038/s41568-019-0216-7. View

Rondinelli B, Gogola E, Yucel H, Duarte A, van de Ven M, van der Sluijs R . EZH2 promotes degradation of stalled replication forks by recruiting MUS81 through histone H3 trimethylation. Nat Cell Biol. 2017; 19(11):1371-1378. DOI: 10.1038/ncb3626. View

Maya-Mendoza A, Moudry P, Merchut-Maya J, Lee M, Strauss R, Bartek J . High speed of fork progression induces DNA replication stress and genomic instability. Nature. 2018; 559(7713):279-284. DOI: 10.1038/s41586-018-0261-5. View

Yang G, Chen Y, Wu J, Chen S, Liu X, Singh A . Poly(ADP-ribosyl)ation mediates early phase histone eviction at DNA lesions. Nucleic Acids Res. 2020; 48(6):3001-3013. PMC: 7102957. DOI: 10.1093/nar/gkaa022. View

Nero C, Ciccarone F, Pietragalla A, Duranti S, Daniele G, Salutari V . Ovarian Cancer Treatments Strategy: Focus on PARP Inhibitors and Immune Check Point Inhibitors. Cancers (Basel). 2021; 13(6). PMC: 7999042. DOI: 10.3390/cancers13061298. View

Somyajit K, Mishra A, Jameei A, Nagaraju G . Enhanced non-homologous end joining contributes toward synthetic lethality of pathological RAD51C mutants with poly (ADP-ribose) polymerase. Carcinogenesis. 2014; 36(1):13-24. DOI: 10.1093/carcin/bgu211. View

10.

Edwards S, Evans D, Hope Q, Norman A, Barbachano Y, Bullock S . Prostate cancer in BRCA2 germline mutation carriers is associated with poorer prognosis. Br J Cancer. 2010; 103(6):918-24. PMC: 2948551. DOI: 10.1038/sj.bjc.6605822. View

11.

Strickland K, Howitt B, Shukla S, Rodig S, Ritterhouse L, Liu J . Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer. Oncotarget. 2016; 7(12):13587-98. PMC: 4924663. DOI: 10.18632/oncotarget.7277. View

12.

ONeil N, Bailey M, Hieter P . Synthetic lethality and cancer. Nat Rev Genet. 2017; 18(10):613-623. DOI: 10.1038/nrg.2017.47. View

13.

Cleary J, Aguirre A, Shapiro G, DAndrea A . Biomarker-Guided Development of DNA Repair Inhibitors. Mol Cell. 2020; 78(6):1070-1085. PMC: 7316088. DOI: 10.1016/j.molcel.2020.04.035. View

14.

Reynolds P, Cooper S, Lomax M, ONeill P . Disruption of PARP1 function inhibits base excision repair of a sub-set of DNA lesions. Nucleic Acids Res. 2015; 43(8):4028-38. PMC: 4417162. DOI: 10.1093/nar/gkv250. View

15.

Challa S, Stokes M, Kraus W . MARTs and MARylation in the Cytosol: Biological Functions, Mechanisms of Action, and Therapeutic Potential. Cells. 2021; 10(2). PMC: 7913519. DOI: 10.3390/cells10020313. View

16.

Langelier M, Eisemann T, Riccio A, Pascal J . PARP family enzymes: regulation and catalysis of the poly(ADP-ribose) posttranslational modification. Curr Opin Struct Biol. 2018; 53:187-198. PMC: 6687463. DOI: 10.1016/j.sbi.2018.11.002. View

17.

Marteijn J, Lans H, Vermeulen W, Hoeijmakers J . Understanding nucleotide excision repair and its roles in cancer and ageing. Nat Rev Mol Cell Biol. 2014; 15(7):465-81. DOI: 10.1038/nrm3822. View

18.

Young L, McDonald D, Hendzel M . Kdm4b histone demethylase is a DNA damage response protein and confers a survival advantage following γ-irradiation. J Biol Chem. 2013; 288(29):21376-21388. PMC: 3774405. DOI: 10.1074/jbc.M113.491514. View

19.

Poltronieri P, Miwa M, Masutani M . ADP-Ribosylation as Post-Translational Modification of Proteins: Use of Inhibitors in Cancer Control. Int J Mol Sci. 2021; 22(19). PMC: 8509805. DOI: 10.3390/ijms221910829. View

20.

Ray Chaudhuri A, Callen E, Ding X, Gogola E, Duarte A, Lee J . Replication fork stability confers chemoresistance in BRCA-deficient cells. Nature. 2016; 535(7612):382-7. PMC: 4959813. DOI: 10.1038/nature18325. View